Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
Hirt C, Iannazzo S, Chiroli S, McGarry LJ, le Coutre P, Stenke L, Dahlén T, Lipton JH. Hirt C, et al. Among authors: chiroli s. Appl Health Econ Health Policy. 2019 Aug;17(4):555-567. doi: 10.1007/s40258-019-00489-0. Appl Health Econ Health Policy. 2019. PMID: 31168745
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY, McGarry LJ, Huang H, Lustgarten S, Chiroli S, Iannazzo S. Levy MY, et al. Among authors: chiroli s. Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24. Curr Med Res Opin. 2019. PMID: 30086654
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page